Whittier Trust Co. of Nevada Inc. raised its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 5.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 130,529 shares of the biopharmaceutical company’s stock after acquiring an additional 7,214 shares during the quarter. Whittier Trust Co. of Nevada Inc.’s holdings in Bristol-Myers Squibb were worth $7,998,000 at the end of the most recent reporting period.
Other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its position in shares of Bristol-Myers Squibb by 0.3% during the 2nd quarter. Vanguard Group Inc. now owns 118,661,690 shares of the biopharmaceutical company’s stock worth $6,611,829,000 after purchasing an additional 333,685 shares in the last quarter. BlackRock Inc. grew its position in shares of Bristol-Myers Squibb by 2.4% during the 2nd quarter. BlackRock Inc. now owns 99,454,602 shares of the biopharmaceutical company’s stock worth $5,541,612,000 after purchasing an additional 2,367,864 shares in the last quarter. Dodge & Cox grew its position in shares of Bristol-Myers Squibb by 1.6% during the 2nd quarter. Dodge & Cox now owns 29,579,461 shares of the biopharmaceutical company’s stock worth $1,648,168,000 after purchasing an additional 459,271 shares in the last quarter. Jennison Associates LLC grew its position in shares of Bristol-Myers Squibb by 16.2% during the 3rd quarter. Jennison Associates LLC now owns 26,854,242 shares of the biopharmaceutical company’s stock worth $1,711,689,000 after purchasing an additional 3,735,453 shares in the last quarter. Finally, Northern Trust Corp grew its position in shares of Bristol-Myers Squibb by 3.9% during the 2nd quarter. Northern Trust Corp now owns 24,041,862 shares of the biopharmaceutical company’s stock worth $1,339,612,000 after purchasing an additional 910,496 shares in the last quarter. 71.55% of the stock is currently owned by hedge funds and other institutional investors.
A number of research analysts have issued reports on the stock. TheStreet lowered shares of Bristol-Myers Squibb from a “b” rating to a “c+” rating in a research report on Thursday, March 8th. ValuEngine lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Wednesday, March 7th. Bank of America increased their price target on shares of Bristol-Myers Squibb from $64.00 to $68.00 and gave the stock a “neutral” rating in a research report on Monday, March 5th. DZ Bank lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Wednesday, February 28th. Finally, Jefferies Group set a $72.00 price target on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a research report on Monday, February 26th. Three research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $66.30.
Bristol-Myers Squibb Co (BMY) opened at $66.74 on Friday. The company has a market cap of $108,779.00, a P/E ratio of 112.29, a P/E/G ratio of 2.05 and a beta of 0.98. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.55 and a quick ratio of 1.43. Bristol-Myers Squibb Co has a 52 week low of $51.56 and a 52 week high of $70.05.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Monday, February 5th. The biopharmaceutical company reported $0.68 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.67 by $0.01. The business had revenue of $5.45 billion during the quarter, compared to the consensus estimate of $5.35 billion. Bristol-Myers Squibb had a net margin of 4.85% and a return on equity of 35.43%. The firm’s revenue was up 3.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.63 EPS. equities analysts expect that Bristol-Myers Squibb Co will post 3.2 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, May 1st. Investors of record on Friday, April 6th will be paid a $0.40 dividend. This represents a $1.60 annualized dividend and a yield of 2.40%. The ex-dividend date is Thursday, April 5th. Bristol-Myers Squibb’s payout ratio is 271.19%.
COPYRIGHT VIOLATION WARNING: This article was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/03/16/bristol-myers-squibb-co-bmy-shares-bought-by-whittier-trust-co-of-nevada-inc.html.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.